Tira exclusively launches South Korea’s Dr. Melaxin skincare brand in India
Reliance Retail’s beauty platform Tira has introduced Dr. Melaxin online and at select stores, led by the Korean dermo-cosmetic brand’s Peel Shot range. The launch adds another science-led global skincare label to Tira’s premium beauty assortment.
What happened
Reliance Retail’s Tira exclusively launched South Korean dermo-cosmetic brand Dr. Melaxin in India via its online platform and select stores, led by the Peel
Key facts
- 8-FREE clean formulation standard
- visible improvements cited within four weeks
Why this matters
Dr. Melaxin’s India entry demonstrates Tira’s value as a distribution partner for international beauty brands seeking selective omnichannel market access.
What to watch
- Dr. Melaxin’s pricing versus Korean dermo-cosmetic peers and whether introductory bundles or discounts are required to drive conversion.
- Online reviews, repeat-purchase rates, and social engagement around Peel Shot within the first 60-90 days.
- Expansion into more Tira stores, additional Dr. Melaxin SKUs, or India-specific kits as indicators of early sell-through.
- Competitive announcements from Nykaa, Sephora India, Myntra, and multi-brand beauty retailers involving K-beauty exclusives.
- Regulatory scrutiny or consumer concern around exfoliation and peel-related claims, which could constrain marketing language or adoption.
- Tira is likely to support the launch with dermatologist-led education, ingredient explainers, creator trials, and in-store skin consultations to build trust around Peel Shot.
- Reliance may broaden Dr. Melaxin distribution from select flagship stores to higher-performing Tira locations if online replenishment and repeat rates are strong.
- Tira may use the partnership to negotiate further India exclusives with Korean clinical skincare and scalp-care brands.
- Competitors may counter with exclusive launches in barrier repair, acne care, pigmentation, and at-home peeling categories, where Korean beauty demand is strongest.